These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33199217)

  • 1. The blue palate-A case series of imatinib-related oral pigmentation and literature review.
    Donnell CC; Walton RL; Carrozzo M
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Jan; 131(1):49-61. PubMed ID: 33199217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal pigmentation of the hard palate in a patient taking imatinib.
    Lyne A; Creedon A; Bailey BM
    BMJ Case Rep; 2015 Apr; 2015():. PubMed ID: 25883257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review.
    Oliveira SR; de Azevedo Branco LG; Rocha AL; Travassos DV; Magalhães GHR; Fonseca FP; Mesquita RA; Abreu LG; da Silva TA
    Clin Oral Investig; 2019 Dec; 23(12):4371-4382. PubMed ID: 30968242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib-induced diffuse hyperpigmentation of the oral mucosa, the skin, and the nails in a patient affected by chronic myeloid leukemia: report of a case and review of the literature.
    Di Tullio F; Mandel VD; Scotti R; Padalino C; Pellacani G
    Int J Dermatol; 2018 Jul; 57(7):784-790. PubMed ID: 29417559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Large Gray-Blue Macule on the Hard Palate as an Adverse Effect of Imatinib.
    Lueken N; Kaune KM; Zutt M
    Dtsch Arztebl Int; 2019 Feb; 116(6):95. PubMed ID: 30892185
    [No Abstract]   [Full Text] [Related]  

  • 6. Hyperpigmentation due to imatinib: A rare case of cutaneous involvement.
    Rehman H; Hakim N; Sugarman R; Seetharamu N; Saif MW
    J Oncol Pharm Pract; 2020 Sep; 26(6):1511-1515. PubMed ID: 32067560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib mesylate induced erythroderma: A rare case series.
    Kumar S; Mahajan BB; Kaur S; Banipal RP; Singh A
    J Cancer Res Ther; 2015; 11(4):993-6. PubMed ID: 26881566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases.
    Mattsson U; Halbritter S; Mörner Serikoff E; Christerson L; Warfvinge G
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2011 May; 111(5):e12-6. PubMed ID: 21330162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib.
    Bombeccari GP; Garagiola U; Pallotti F; Rossi M; Porrini M; Giannì AB; Spadari F
    Maxillofac Plast Reconstr Surg; 2017 Dec; 39(1):37. PubMed ID: 29230387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib-associated hyperpigmentation of the palate in post-HSCT patient.
    Resende RG; Teixeira RG; Vasconcelos Fde O; Silva ME; Abreu MH; Gomez RS
    J Craniomaxillofac Surg; 2012 Jul; 40(5):e140-3. PubMed ID: 21862339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case series of imatinib-induced generalized hypopigmentation and progression of existing acquired dermal melanocytosis.
    Kok WL; Chen Q; Lee SSJ; Chua SH; Ng SK
    J Dermatolog Treat; 2017 Dec; 28(8):762-763. PubMed ID: 28481685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients.
    Vinay K; Yanamandra U; Dogra S; Handa S; Suri V; Kumari S; Khadwal A; Prakash G; Lad D; Varma S; Malhotra P
    Int J Dermatol; 2018 Mar; 57(3):332-338. PubMed ID: 29266186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cystic acne due to imatinib therapy for chronic myelocytic leukemia.
    Hwang A; Iskandar A; Del Rosario M; Dasanu CA
    J Oncol Pharm Pract; 2019 Jun; 25(4):972-974. PubMed ID: 29498323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia.
    Prabhash K; Biswas G; Prasad N; Karant N; Sastry PS; Parikh PM
    Indian J Dermatol Venereol Leprol; 2006; 72(1):63-4. PubMed ID: 16481719
    [No Abstract]   [Full Text] [Related]  

  • 15. Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT.
    Khoo TL; Catalano A; Supple S; Chong L; Yeoh SC; Yeung S; Iland H
    Leuk Lymphoma; 2013 Jan; 54(1):186-8. PubMed ID: 22712835
    [No Abstract]   [Full Text] [Related]  

  • 16. Imatinib-induced melanonychia in a patient of chronic myeloid leukaemia: rarely reported side effect.
    Thapa M; Chaturvedi A
    Postgrad Med J; 2020 May; 96(1135):296-297. PubMed ID: 31672761
    [No Abstract]   [Full Text] [Related]  

  • 17. Erythroderma: An unusual manifestation of imatinib - A rare case report.
    Kataria P; Patel A; Kendre P; Tahiliani N; Mule T; Bohra M
    J Cancer Res Ther; 2022; 18(1):253-256. PubMed ID: 35381793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
    Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
    Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature.
    Wong M; Sade S; Gilbert M; Klieb HB
    Dermatol Online J; 2011 May; 17(5):4. PubMed ID: 21635826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity.
    Musolino C; Allegra A; Mannucci C; Russo S; Alonci A; Maisano V; Calapai G; Gangemi S
    Turk J Haematol; 2015 Jun; 32(2):168-71. PubMed ID: 26316486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.